IL33 and neoplasm: In this study, we demonstrated that IL-33 within the tumor microenvironment (TME), primarily secreted by cancer-associated fibroblasts (CAFs), can enhance DNA damage-resistance in tumor cells by activating the MAPK/NHEJ pathway.